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Abidi and colleagues recently reported that eosinopenia con-
stitutes a good diagnostic marker in distinguishing between
noninfection and infection, but is a moderate marker in
discriminating between systemic inflammatory response
syndrome and infection in newly admitted critically ill patients
[1]. They propose that eosinopenia may become a helpful
clinical tool in intensive care unit (ICU) practices. They
included different types of severe infections, however, and
therefore the utility of eosinopenia for a particular kind of
infection is not approached.
We would like to describe our experience with a homo-
geneous group of HIV-infected patients suffering from
community-acquired pneumonia (CAP), a severe clinical
condition that sometimes can lead the patient to the ICU. We
consecutively included 137 HIV-infected patients with a firm
diagnosis of CAP based on Infectious Diseases Society of
America criteria, whose clinical, analytical and outcome data
were prospectively recorded. We split our series into different
groups depending on the patient requiring ICU admission
(n = 29) or not requiring ICU admission (n = 108), and
depending on inhospital patient survival (n = 132) or inhospital
death (n = 5).
The results are presented in Table 1. As can be seen,
eosinopenia was not associated with a higher ICU admission
rate or with higher mortality. Accordingly, we believe that the
total eosinophil count and/or eosinopenia have little (if any)
value in predicting the severity of CAP in HIV-infected
patients.
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CAP = community-acquired pneumonia; ICU = intensive care unit.
Table 1
Relationship between some analytical parameters and severity of community-acquired pneumonia in HIV-infected patientsa
ICU admission Mortality
No Yes P value* Discharged alive Death P value*
C-reactive protein (mg/dl) 16.3 ± 12.6 18.8 ± 12.1 0.26 17.2 ± 12.7 10.7 ± 14.0 0.22
Total leukocyte count (cells/ml) 10,410 ± 5,810 14,100 ± 9,820 0.08 11,230 ± 7,120 7,580 ± 3,902 0.25
Total eosinophil count (cells/ml) 114 ± 155 114 ± 145 0.68 115 ± 159 98 ± 31 0.43
Eosinopenia (<40 cells/ml) 0.94 0.59
No 85 (79%) 22 (76%) 112 (77%) 5 (100%)
Yes 23 (21%) 7 (24%) 30 (27%) 0 (0%)
aSeverity of community-acquired pneumonia judged by the need for intensive care unit (ICU) admission and by mortality. Data presented as the
mean ± standard deviation or n (%). *Calculated by means of the Mann–Whitney nonparametric test (quantitative variables) and the chi-square test
or Fisher’s exact test (qualitative variables).Page 2 of 2
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From the emergency department point of view – departments
that usually are overcrowded [2] – any tool that allows the
physicians to better approach the severity of the infections in
general, and the severity of the HIV-infected patients
developing CAP in particular, would be welcomed [3,4].
Eosinophils seem to fail to fulfil this commitment, while other
classic analytical markers, such as the total leukocyte count
or C-reactive protein values, remain with greater prognostic
value [5].
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We thank the editor for giving us the opportunity to respond
to the comments raised by Dr Perello and colleagues. In our
experience, eosinopenia is a good marker for the diagnosis of
sepsis on ICU admission [1]. It discriminates well between
noninfected patients and infected patients. Our study
population did not include HIV-infected patients. Moreover,
the prognostic value of eosinopenia was not tested. We
therefore cannot ascertain the value of this marker to predict
mortality in the ICU.
Concerning the severity of infection, Perello and colleagues
found no association between eosinopenia and a higher ICU
admission rate among HIV-infected patients suffering from
CAP. This finding was also reported in our work involving a
diverse group of critically ill adults admitted to the ICU. The
lack of differences between sepsis, severe sepsis and septic
shock was noted in our study. This was not surprising
because of the suggested floor effect of eosinopenia.
Furthermore, in the study of Perello and colleagues there was
no noninfection group enrolled (HIV patients without CAP) to
test the value of eosinopenia in the diagnosis of sepsis (CAP)
among HIV-infected patients. Gil and colleagues showed in
an internal medicine department that inflammatory syndrome
associated with eosinophils <40 cells/mm3 is related to
bacterial infectious diseases [6]. If we take into account the
hypothetical mechanism of eosinopenia, which is the
migration of eosinophils to the inflammatory site [7,8], we
think it may be interesting if Perello and colleagues used the
eosinophil cutoff value (40 cells/ml) to test the value of
eosinopenia in distinguishing HIV-infected patients with CAP
and those without CAP.
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